APLS - Apellis Pharmaceuticals, Inc.

QQQ $ 473.29 $ -0.14 (-0.03 %)

DIA $ 413.53 $ 0.90 (0.22 %)

SPY $ 560.29 $ 0.02 (0 %)

TLT $ 100.29 $ -0.19 (-0.19 %)

GLD $ 238.41 $ 0.82 (0.35 %)

Previous Close

$ 36.78

Open

$ 36.31

Bid

$ 36.79 x 200

Ask

-- x --

Day's Range

$ 36.31 - $ 36.93

52 Week Range

$ 33.49 - $ 73.80

Volume

1,735,885

Average Volume

Market Cap

4.48B

Beta (5Y Monthly)

$ 0.90

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-01-2024	06-30-2024	10-Q
2	05-07-2024	03-31-2024	10-Q
3	02-27-2024	12-31-2023	10-K
4	11-01-2023	09-30-2023	10-Q
5	07-31-2023	06-30-2023	10-Q
6	05-04-2023	03-31-2023	10-Q
7	02-21-2023	12-31-2022	10-K
8	11-07-2022	09-30-2022	10-Q
9	08-08-2022	06-30-2022	10-Q
10	05-04-2022	03-31-2022	10-Q
11	02-28-2022	12-31-2021	10-K
12	11-08-2021	09-30-2021	10-Q
13	08-09-2021	06-30-2021	10-Q
14	04-28-2021	03-31-2021	10-Q
15	02-25-2021	12-31-2020	10-K
16	11-02-2020	09-30-2020	10-Q
17	07-30-2020	06-30-2020	10-Q
18	04-29-2020	03-31-2020	10-Q
19	02-27-2020	12-31-2019	10-K
20	11-05-2019	09-30-2019	10-Q
21	07-31-2019	06-30-2019	10-Q
22	05-07-2019	03-31-2019	10-Q
23	02-26-2019	12-31-2018	10-K
24	11-13-2018	09-30-2018	10-Q
25	07-31-2018	06-30-2018	10-Q
26	04-30-2018	03-31-2018	10-Q
27	03-19-2018	12-31-2017	10-K
28	12-20-2017	09-30-2017	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

JP Morgan Maintains Overweight on Apellis ...
08/13/2024 12:31:23

JP Morgan analyst Anupam Rama maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Overweight and lowers the price target ...

UBS Maintains Buy on Apellis Pharmaceutica...
08/09/2024 14:48:37

UBS analyst Eliana Merle maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target from $85 to ...

Wedbush Maintains Neutral on Apellis Pharm...
08/09/2024 13:58:51

Wedbush analyst Laura Chico maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Neutral and raises the price target from ...

Goldman Sachs Maintains Buy on Apellis Pha...
08/09/2024 11:57:44

Goldman Sachs analyst Salveen Richter maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and raises the price target...

Baird Maintains Outperform on Apellis Phar...
08/09/2024 11:15:20

Baird analyst Colleen Kusy maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Outperform and raises the price target fro...

Needham Reiterates Buy on Apellis Pharmace...
08/09/2024 10:31:19

Needham analyst Joseph Stringer reiterates Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $85 price target.

apellis-pharmaceuticals-pegcetacoplan-meets-primary-goal-in-late-stage-study-in-patients-with-rare-kidney-diseases

Apellis Pharmaceuticals' Pegcetacoplan Mee...
08/08/2024 16:53:31

Swedish Orphan Biovitrum and Apellis Pharmaceuticals released topline results from the Phase 3 VALIANT study of pegcetacoplan f...

Trading Halt: Halt status updated at 7:25:...
08/08/2024 11:25:03

Apellis And Sobi Announce Phase 3 VALIANT ...
08/08/2024 11:20:25

Apellis To Host Conference Call At 8:00 AM ET

Trading Halt: Halted at 6:55:00 a.m. ET - ...
08/08/2024 10:55:03

HC Wainwright & Co. Maintains Buy on Apell...
08/02/2024 21:21:55

HC Wainwright & Co. analyst Douglas Tsao maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price...

Goldman Sachs Maintains Buy on Apellis Pha...
08/02/2024 16:24:24

Goldman Sachs analyst Salveen Richter maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target...

Critical Insights From Apellis Pharmaceuti...
08/02/2024 12:00:16

Needham Reiterates Buy on Apellis Pharmace...
08/02/2024 10:53:13

Needham analyst Joseph Stringer reiterates Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $85 price target.

CORRECTION: Apellis Pharmaceuticals Q2 202...
08/01/2024 12:06:04

Jefferies Maintains Buy on Apellis Pharmac...
07/31/2024 18:04:23

Jefferies analyst Akash Tewari maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $80 price target.

Watching Apellis Pharmaceuticals; Traders ...
07/31/2024 14:55:34

https://fis.fda.gov/sense/app/95239e26-e0be-42d9-a960-9a5f7f1c25ee/sheet/45beeb74-30ab-46be-8267-5756582633b4/state/analysis

Baird Maintains Outperform on Apellis Phar...
07/26/2024 11:15:29

Baird analyst Colleen Kusy maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Outperform and lowers the price target fro...

Baird Maintains Outperform on Apellis Phar...
07/23/2024 20:42:14

Baird analyst Colleen Kusy maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Outperform and maintains $100 price target.

Peeling Back The Layers: Exploring Apellis...
07/17/2024 17:01:42